Patterns of susceptibility of 45 Proteus penneri clinical isolates to 14 antimicrobial agents were evaluated by a macrobroth dilution method. All strains were highly susceptible to ceftizoxime, ceftazidime, moxalactam, cefoxitin, gentamicin, tobramycin, netilmicin, and, with few exceptions, to amikacin, piperacillin, and cefoperazone. Most strains were susceptible to cefotaxime and ceftriaxone. All strains were resistant to cefazolin and cefsulodin.
Proteus penneri has been recently recognized as a new member of the tribe Proteeae (4, 12) . Previously, it had been classified as indole-negative P. vulgaris biogroup 1 . P. penneri is indole, esculin, and salicin negative after 48 h of incubation and exhibits a narrow zone of inhibition around a 30-jig chloramphenicol disk (usually <14 mm). These characteristics are essential in differentiating P. penneri from P. vulgaris biogroup 2 (indole, salicin, and esculin positive, chloramphenicol susceptible) and from P. vulgaris biogroup 3 (indole positive, salicin and esculin negative). The chloramphenicol resistance pattern of the latter biogroup has not yet been satisfactorily delineated (4 5, 6, 13, 14, 18 ). There appears to be a marked susceptibility of P. penneri to ceftizoxime (MIC90, 0.25 ,ug/ml), in contrast to P. vulgaris (MIC90s, 2 and 12.5 ,ug/ml [references 13 and 17, respectively]). Cefoxitin was only slightly more active against P. penneri (MIC90, 4 ,ug/ml) than against P. vulgaris (MIC90s, 6.25, 8, 16, 32, and 50 ,ug/ml [references 1, 5, 9, 13, and 18, respectively]). In a recent report, P. penneri strains were reported to be more resistant to the newer semisynthetic ureidopenicillins, azlocillin and mezlocillin (3) . However, in our study, P. penneri strains were generally found to be susceptible to piperacillin (MIC90, 16 ,ug/ml). Although the patterns of susceptibility to these three ureidopenicillins, ceftizoxime, and ceftriaxone suggest a basis for differentiating P. penneri from P. vulgaris, more isolates need to be studied. The overall evaluation of the in vitro activity of ceftizoxime, ceftazidime, moxalactam, and cefoxitin suggests that these agents may prove to be clinically useful in treating infections caused by P. penneri. All four aminoglycosides tested were extremely active against P. penneri and should therefore be considered as drugs of choice for the treatment of systemic infections caused by susceptible P. penneri strains.
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